SBIR/STTR Research Award

Intestinal Drug Transporters in Veterinary Animals

Award identifier 182fb910c96625445143a3c0ea43d034b01b494147fe1df4e22196ca874267edAwarding agency Department of Health and Human Services · Food and Drug Administration

Award amount

$168,400

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Food and Drug Administration
Recipient company
Apricity Therapeutics
Proposal award date
2022-09-20
Contract end date
2023-08-31
UEI
H6EANYTE9RY1
Solicitation number
PA21-259
Topic code
FDA

Research abstract

Intestinal Drug Transporters in Veterinary Animals Intestinal transporters in the ATP Binding Cassette Family (ABC) reduce the absorption of many xenobiotics including prescription drugs. ABCG2 encodes BCRP, an important transporter that is highly expressed in the intestine as well as other barrier tissues such as the Blood Brain Barrier. BCRP limits the oral bioavailability of its substrates and therefore candidate drugs that are found to highly interact with BCRP are often discarded during drug development. Only those with limited or no interactions with BCRP are selected for further development. However, for veterinary drug development, cell lines expressing the appropriate species orthologs of BCRP are not available. Since species differences in the substrate and inhibitor selectivity of transporters are likely to occur, the lack of cell lines expressing species orthologs of transporters represents an enormous gap for veterinary drug development. The goals of this Phase I SBIR research are to create and characterize cell lines and yeast strains stably expressing veterinary animal BCRP from dog, cat, sheep and pig. The cell lines and yeast strains will serve as resources for drug developers, and will represent innovative “alternative methods, in support of replacement/reduction/refinement for activities involving animal research.” In studies under aim 1, we will create stable cell lines and yeast strains expressing the species orthologs of BCRP. In aim 2, we will create robust assays and use model substrates and inhibitors of BCRP to characterize species differences in the substrate and inhibitor specificity of the transporter. Methods used in the proposed studies include technologies for creation of cell lines stably expressing the transporter orthologs, and isotopic uptake and flux assays in cells. Yeast transformation procedures and cytotoxicity assays will also be applied. Collectively these studies will enable veterinary drug development by providing much needed cell lines for predicting drug absorption. The cell lines will reduce the reliance on trial-and-error experimental approaches in animals.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2012–2022). Reported award amounts total $1,364,462. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.